ozlodip
douglas pharmaceuticals limited - amlodipine besilate 6.934mg equivalent to amlodipine 5 mg - tablet - 5 mg - active: amlodipine besilate 6.934mg equivalent to amlodipine 5 mg excipient: colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose sodium starch glycolate - indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of ozlodip, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensinconverting enzyme inhibitor.
procur
douglas pharmaceuticals limited - cyproterone acetate 100mg; ; - tablet - 100 mg - active: cyproterone acetate 100mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose povidone - in men · antiandrogen treatment in inoperable carcinoma of the prostate
procur
douglas pharmaceuticals limited - cyproterone acetate 50mg; ; - tablet - 50 mg - active: cyproterone acetate 50mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose povidone - in men · antiandrogen treatment in inoperable carcinoma of the prostate
solox
douglas pharmaceuticals limited - lansoprazole 15mg (lansoprazole (r,s racemic mixture)); - capsule - 15 mg - active: lansoprazole 15mg (lansoprazole (r,s racemic mixture)) excipient: gelatin hypromellose macrogol 6000 mannitol meglumine methacrylic acid - ethyl acrylate copolymer polysorbate 80 purified talc purified water quinoline yellow sodium laurilsulfate sugar spheres titanium dioxide - healing and long-term management of reflux oesophagitis healing and maintenance therapy for patients with duodenal ulcer healing of benign gastric ulcer lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists
solox
douglas pharmaceuticals limited - lansoprazole 30mg (lansoprazole (r,s racemic mixture) ); - capsule - 30 mg - active: lansoprazole 30mg (lansoprazole (r,s racemic mixture) ) excipient: gelatin hypromellose macrogol 6000 mannitol meglumine methacrylic acid - ethyl acrylate copolymer polysorbate 80 purified talc sodium laurilsulfate sugar spheres titanium dioxide water - healing and long-term management of reflux oesophagitis healing and maintenance therapy for patients with duodenal ulcer healing of benign gastric ulcer lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists
temaccord
douglas pharmaceuticals limited - temozolomide 100mg; - capsule - 100 mg - active: temozolomide 100mg excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.
temaccord
douglas pharmaceuticals limited - temozolomide 140mg; - capsule - 140 mg - active: temozolomide 140mg excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.
temaccord
douglas pharmaceuticals limited - temozolomide 180mg; - capsule - 180 mg - active: temozolomide 180mg excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.
temaccord
douglas pharmaceuticals limited - temozolomide 20mg; - capsule - 20 mg - active: temozolomide 20mg excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.
temaccord
douglas pharmaceuticals limited - temozolomide 250mg; - capsule - 250 mg - active: temozolomide 250mg excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.